A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.
Inclusion Criteria:
For inclusion in the study, patients should fulfill the following criteria:
Exclusion Criteria:
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
information.center@astrazeneca.com1-877-240-9479
Ste-Foy, Quebec G1V 4G2, Canada
Ginowan-shi, 901-2725, Japan
Hidaka-shi, 350-1298, Japan
Kurume-shi, 830-0011, Japan
Shinjuku-ku, 160-8582, Japan
Suita-shi, 565-0871, Japan
Sunto-gun, 411-8777, Japan
Toon-Shi, 791-0295, Japan
Guadalajra, 44260, Mexico
Hospitalet deLlobregat, 08907, Spain
Muang, 50200, Thailand